245 First Street, 18th Floor
About FogPharmaFogPharma is developing transformative new medicines exploiting the unique ability of cell-penetrating miniproteins to access validated "undruggable" intracellular disease drivers and to home in on therapeutically beneficial tissues in the human body.
Founder: Dr. Greg Verdine
8 articles with FogPharma
FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
FogPharma ® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability ™ Platform FogPhama’s proprietary Helicon™ peptides represent a new class of precision medicines that combines the targeting strength and specificity of antibodies with the cell penetration of small molecules
FogPharma today announced the appointment of Tony Gibney as Chief Financial Officer and Chief Business Officer.
Cambridge Discovery Park Building 400-500 Will be New Headquarters for FogPharma and LifeMine Therapeutics
The Bulfinch Companies, Inc. announced it has signed a 114,490 SF lease with FogPharma in building 400 at Cambridge Discovery Park.
5/10/2019Pharma and biotech companies strengthen their leadership teams with new hires at Immunocore, Eisai, Kyn, Bicycle, and more.
FogPharma Strengthens New Modality Drug Hunting Team with Appointment of Howard Stern as Chief Scientific Officer and Peter Fekkes as Vice President of Discovery Bioscience
FogPharma announced the appointment of Howard Stern, M.D., Ph.D., as Chief Scientific Officer.
CEO of Tango Therapeutics and Venture Partner at Third Rock Ventures to lend her expertise to FogPharma as the Company continues to advance a powerful new class of medicines - cell-penetrating miniproteins - for the treatment of serious diseases
Company is pioneering a powerful new class of medicines - cell-penetrating miniproteins - with an on-demand drug discovery platform for the treatment of serious diseases driven by intractable targets